The Oncologist

02/17/2026

The role of patient navigation programs in early cancer care in Mexico: a multi-case qualitative study
https://doi.org/10.1093/oncolo/oyaf314

02/13/2026

Adjuvant chemotherapy improved survival for patients with an LNR below 11%, while it provided no benefit for those with higher LNRs. An LNR threshold of 11% can personalize treatment, identifying those who may need chemotherapy or more intensive treatments like chemoradiotherapy.

AbstractBackground. The lymph node ratio (LNR) has emerged as an important prognostic factor in various cancers, including esophageal squamous cell carcino

02/12/2026

FDA GI cancer drug approvals rely on pathways, surrogate endpoints, and trials. From 2006–2025, survival gains were modest 2.1 mo, and few met substantial clinical , raising concerns about meaningful patient outcomes
https://doi.org/10.1093/oncolo/oyaf381

02/11/2026

A retrospective look at registry shows patient choice of oncologist in is driven by and , not age, gender, or . disease and strong reduce second opinions

Abstract. Choice of oncologist by patients with pancreatic cancer is a complex personal decision. We conducted a retrospective analysis of the Pancreatic C

02/10/2026

Advanced ampullary carcinoma is rare and lacks guidelines. In trials, had modest outcomes 24% ~8 mo, ~12 mo similar to other . This analysis supports as standard but underscores need for molecularly guided, collaborative trials

Abstract. Ampullary carcinoma (AC) is a rare malignancy. It is often classified within biliary tract cancers (BTC) but lacks dedicated treatment guidelines

02/09/2026

Analysis of 1,935 and pancreatic shows older 👴 and male *x lead to lower , tumor ,🧬 and immune profiles. Distinct and *x specific patterns may inform future and care

AbstractPurpose. Age and s*x are known to influence outcomes in neuroendocrine neoplasms (NENs), yet their molecular determinants remain poorly defined. We

02/06/2026

In stage II/III **al 💉☢️, adjuvant or showed no or benefit over 5-FU alone. Early closure limited power. Outcomes favor approaches.
https://doi.org/10.1093/oncolo/oyaf416

02/05/2026

This study utilizes interviews with and . Metastatic cancer causes heavy symptom burden 🥴😵‍💫with major emotional and functional impacts 😰😭. Current for are lacking, disease specific are needed
https://doi.org/10.1093/oncolo/oyaf427

02/02/2026

This review proposes a framework to assess the appeal and return on investment for patients participating in interventional . It aims to help investigators evaluate the types of trials being offered across diverse patient populations.
https://doi.org/10.1093/oncolo/oyaf313

01/30/2026

The Past, Present, and Future of Myeloma Staging and Risk Prognostication
https://doi.org/10.1093/oncolo/oyaf299

01/28/2026

A real-world, multi-institutional retrospective comparative analysis of 1st line atezo/bev versus treme/durva in unresectable HCC
https://doi.org/10.1093/oncolo/oyaf286

01/27/2026

New research reveals key risk factors for ICI-associated myocarditis. Elevated cTnI, reduced LVEF, & concomitant myositis predict severe outcomes. This novel framework helps clinicians optimize treatment & set realistic expectations for ICI-myocarditis.

AbstractBackground. Immune checkpoint inhibitors-related myocarditis (ICI-myocarditis) is a rare but potentially lethal complication of cancer immunotherap